Relmada Therapeutics(RLMD) - 2025 Q4 - Annual Report
Relmada TherapeuticsRelmada Therapeutics(US:RLMD)2026-03-19 20:25
Transcript

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 000-55347 Relmada Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 45-5401931 (State or other jurisdiction o ...